Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : HMSC- A simple breast cancer screening device -- Ignore unavailable to you. Want to Upgrade?

To: FCC who wrote (197)	5/7/1998 9:33:00 AM
From: Dante Sinferno	Respond to of 246

Wow...even Datek has no shares to borrow. Thought I might play a small one day short after thinking about it and Datek has no shares. When they are out , everyone is out IMO. Next month's short interest should be verrrry interesting. Rob

To: FCC who wrote (197)	5/7/1998 9:18:00 PM
From: Geigartt	Read Replies (1) \| Respond to of 246

Lessee, now would a legit company wait 6 months after introducing a product to announce trials? They need some good news pronto. The last 3 days hmsc has gone into $4 territory.

To: FCC who wrote (197)	5/8/1998 7:23:00 AM
From: Q.	Read Replies (1) \| Respond to of 246

FCC, where did you get your info about when clinical trials results are expected? The 10k annual report filed in March said only the following about trials: <<Clinical Trials The Company commenced post-marketing clinical trials in the first quarter of 1998. The primary objective of these trials is to provide health care professionals with additional clinical data for application in the clinical setting for screening of breast disease, including breast cancer.>> <<The Company's future liquidity and capital funding requirements will depend on numerous factors, including results of clinical trials, the extent to which the BreastAlert device gains market acceptance, the costs and timing of expansion of sales, marketing and manufacturing activities and competition. >>